Clinical trials: Neoadjuvant Chemotherapy
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Exploring the safety and effectiveness of neoadjuvant therapy using benmelstobart combined with anlotinib and chemotherapy for locally advanced squamous cell carcinoma of the head and neck patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
- Trial name
- NCT06699498
- Testing
- Benmelstobart, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Head and Neck Squamous Cell Carcinoma, HNSCC
Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and Neck Squamous Cell Carcinoma
This prospective, single-arm, multicenter phase II trial aims to evaluate the efficacy and safety of neoadjuvant beccotatug vedotin combined with pucotenlimab and cisplatin in patients with locally advanced epidermal growth…
- Trial name
- NCT07814287
- Testing
- Becotatug Vedotin, Pucotenlimab, and Cisplatin
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Xuekui Liu
Estrogen Receptor Negative, HER2/Neu Negative
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
- Trial name
- NCT02744053
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-PD-1 immunotherapy. The trial is designed using a pick-the-winner strategy.
- Trial name
- TORCH-G (NCT06728657)
- Testing
- HFRT targeted to the primary lesion and positive lymph nodes, PULSAR targeted to the primary lesion and positive lymph nodes, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Cholangiocarcinoma, Intrahepatic
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative…
- Trial name
- NCT04506281
- Testing
- neoadjuvant treatment
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells.
- Trial name
- NCT00727441
- Testing
- GVAX pancreatic cancer vaccine, cyclophosphamide
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peripheral Neuropathy Due to Chemotherapy
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
The present study aims to evaluate the effectiveness of acupuncture in the treatment of chemotherapy drug paclitaxel induced peripheral neuropathy in patients with early stage breast cancer
- Trial name
- NCT04461977
- Testing
- True acupuncture
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Resectable Pancreatic Adenocarcinoma
A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma
Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected to rise to the second leading cause of cancer-related mortality.
- Trial name
- NCT05066802
- Testing
- neoadjuvant modified FOLFIRINOX
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Peripheral Neuropathy in Breast Cancer Patient
Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy
The trial will utilize Nutraceuticals (Vitamin D 2000IU oral once daily, Vitamin B6 100 mg oral once daily, Vitamin B12 100 mcg oral once daily, Omega-3 Fatty Acids 900 mg oral three times a day) in patients treated with…
- Trial name
- CIPN (NCT02795572)
- Testing
- Vitamin D, Vitamin B6, Vitamin B12
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of…
- Trial name
- NCT06500208
- Testing
- Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Squamous Cell Carcinoma (ESCC)
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07682376
- Testing
- Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Harbin Medical University
Breast Cancer
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
- Trial name
- NCT06227117
- Testing
- Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Bladder Cancer
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.
- Trial name
- BLAST (NCT02885974)
- Testing
- Celecoxib, Gemcitabine, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
Locally Advanced Breast Cancer
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
Aberrant DNA methylation and histone deacetylation participate in cancer development and progression, as epigenetic alterations are common to breast cancer, in this phase II study, the demethylating hydralazine plus the HDAC…
- Trial name
- NCT00395655
- Testing
- Hydralazine and magnesium valproate administration, Core-needle biopsy of the breast
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- National Institute of Cancerología
Breast Cancer
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
This study will evaluate whether adding QL1706 (iparomlimab and tuvonralimab) to neoadjuvant endocrine therapy improves tumor response in patients with hormone receptor-positive (HR-positive), human epidermal growth factor…
- Trial name
- NCT07782840
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
This phase II trial studies how well pembrolizumab with or without chemotherapy works when given before surgery in treating patients with stage I-IIIA non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT04061590
- Testing
- Cisplatin, Pembrolizumab, Pemetrexed
- Where
- United States
- Sponsor
- University of California, San Francisco
Chemotherapy Effect
Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
Neoadjuvant chemotherapy for advanced-stage gastric cancer is justified by various studies, however, there was not any large scale randomized controlled trial (RCT) to support it until German oncologist introduced a novel…
- Trial name
- NCT03646591
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Ovarian Cancer
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors.
- Trial name
- NCT07125391
- Testing
- Propranolol Hydrochloride, Paclitaxel liposome, Carboplatin
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Bai-Rong Xia
Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma
This is a single-arm, multicenter, exploratory study to evaluate the efficacy and safety of AK104 in combination with cisplatin and paclitaxel in the treatment of resectable locally advanced esophageal squamous carcinoma.
- Trial name
- NCT05833971
- Testing
- cadonilimab+chemotherapy
- Volunteers
- 43 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol
Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma
This is a single-center, prospective, open-label, single-arm, phase Ib/II study evaluating the safety and efficacy of neoadjuvant propranolol combined with SOX chemotherapy and toripalimab in patients with resectable locally…
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol, SOX Chemotherapy, Toripalimab
- Trial name
- NCT07727993
- Testing
- propranolol, Toripalimab, Oxaliplatin
- Volunteers
- 49 people
- Sponsor
- Ting Liu